Tiagabine

Drug Profile

Tiagabine

Alternative Names: A-70569; CEP-6671; Gabitril; NO-050328; NO-328; Tiagabine hydrochloride

Latest Information Update: 23 Jan 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Developer Cephalon; Novo Nordisk; Teva Pharmaceutical Industries
  • Class Antiepileptic drugs; Nipecotic acids; Small molecules
  • Mechanism of Action GABA uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Discontinued Anxiety disorders; Insomnia; Neuropathic pain

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 14 Oct 2011 Cephalon has been acquired by Teva Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top